Potential endocrine (i.e., thyroid hormones) markers that can be clinically measured in the prenatal period may provide improved clinical suspicion of PMD and ensure subsequent preventative measures for the postpartum period. The gene discussed is TG; the disease is Pelizeaus-Merzbacher spectrum disorder.